Among 11 patients with LMD due to NSCLC with ALK (n = 9) or ROS1 (n = 2) mutations, lorlatinib therapy demonstrated an intracranial objective response rate (ORR) of 45%; survival data was not provided [88]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.